BTN3A2 and ovarian carcinoma: Recent studies have found that a higher expression of BTN3A2 in ovarian cancer and triple negative breast cancer is positively correlated with increased T cell infiltration and a better prognosis (22, 23), but other studies have reported that BTN3A2 is associated with poor prognosis in gastric cancer and pancreatic ductal adenocarcinoma (PDAC) (22, 24).